Yüksel Ürün: The final analysis of the IMvigor130

Yüksel Ürün, Professor at the Department of Medical Oncology, Ankara University School of Medicine, recently posted on X/Twitter:

“The final analysis of the IMvigor130:

• Atezolizumab didn’t significantly improve overall survival compared to chemotherapy
• It may still be an effective alternative, especially for patients with high PD-L1 expression who are ineligible for cisplatin.”

For details click here.
Source: Yüksel Ürün/X